Adding belzutifan to pembrolizumab after kidney cancer surgery cuts recurrence risk by 28%, helping high-risk patients stay ...

With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

Arcus Biosciences (NYSE:RCUS) reported positive late stage efficacy results for casdatifan, its investigational HIF-2a inhibitor, in late line renal cell carcinoma. The company released biomarker ...

But quality-of-life findings should be considered alongside DFS benefit, says researcher ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Earlier analyses demonstrated strong local tumor control, with nearly nine in 10 patients remaining free of recurrence at ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

IceCure Medical (ICCM) announced the completion of its last patients’ five-year follow up evaluation in its ICESECRET ...

Eisai has a position in kidney cancer with Lenvima (lenvatinib), a kinase inhibitor that is approved for use in combination with MSD's cancer immunotherapy Keytruda (pembrolizumab) as a first-line ...

Most people with kidney cancer first come to Fred Hutch after being diagnosed by another physician, often their primary care physician. We confirm this diagnosis and other details about your disease ...

A 74-year-old man, diagnosed with advanced kidney cancer and facing an 80% damaged kidney, opted for natural treatment at ...